Achieve Life Sciences received a Complete Response Letter from the FDA citing manufacturing and labeling issues for cytisinicline, despite positive clinical trial results showing no safety or efficacy concerns. The company is working to resolve these manufacturing problems while maintaining a cash runway supported by $180 million in upfront financing, aiming for potential FDA approval in the first half of 2027. Success depends on converting motivated quitters into treated patients and competing effectively against generic alternatives and other cessation therapies. Investors should watch for dilution and arbitration risks as the company transitions toward commercialization.
Achieve Life Sciences is the subject of this update, and here is Pluang's Health-sector market snapshot as of Sep 22, 2026 18:11 WIB: Among 95 priced US Health-sector stocks, 50 rose and 38 fell today. Regeneron Pharmaceuticals Inc (REGN) traded at USD 790.72 with a 1-day change of -0.93%. GeneDx Holdings Corp (WGS) showed a price of USD 96.94 and a 1-day change of -0.91%.
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...
